Trial Profile
A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 23 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 1 Sep 2020.